---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029342"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:42:51.109952+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# KalVista reports Phase 3 KONFIDENT success for sebetralstat, CEO transition, $150M financing

## Summary
- Phase 3 KONFIDENT met all primary and key secondary endpoints; sebetralstat safety profile similar to placebo.
- CEO transition: Benjamin Palleiko appointed CEO, succeeding prior CEO as part of commercial preparation.
- Closed underwritten offering netting ~$150.1M from 7.0M shares and 3.5M pre-funded warrants at $15.25/share.
- Net loss $29.0M ($0.84/sh) for fiscal Q3 ended Jan 31, 2024, vs $21.3M ($0.75) YoY; cash $75.6M.
- NDA submission on track for H1 2024; UK MHRA granted Innovation Passport for sebetralstat.

## SEC filing metadata
- accession: 0000950170-24-029342
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017024029342/0000950170-24-029342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017024029342/kalv-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029342
- JSON: https://secwatch.observer/filing/0000950170-24-029342.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029342.txt

## Key facts
- Earnings Releases
  KalVista Pharmaceuticals, Inc. reported the fiscal quarter ended January 31, 2024 results: net income $29.0 million, EPS $(0.84) per weighted average basic and diluted share.
  - Period: the fiscal quarter ended January 31, 2024
  - Net income: $29.0 million
  - EPS: $(0.84) per weighted average basic and diluted share
  - Result: reported results
  source text: Net loss was $29.0 million, or $(0.84) per weighted average basic and diluted share, for the three months ended January 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017024029342/0000950170-24-029342-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.